nach oben

Journal of Natural Medicines

Erschienen in:

01.01.2012 | Original Paper

Inhibition of cyclooxygenase-2 and inducible nitric oxide synthase by silymarin in proliferating mesenchymal stem cells: comparison with glutathione modifiers

verfasst von: Hamidreza Ahmadi-Ashtiani, Abdolamir Allameh, Hosein Rastegar, Masoud Soleimani, Elham Barkhordari

Erschienen in: Journal of Natural Medicines | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Silymarin, a mixture of flavonolignans, is extracted from milk thistle (Silybum marianum) and has a strong antioxidant activity and exhibits anticarcinogenic, anti-inflammatory, and cytoprotective effects. In this study we attempted to determine whether silymarin and the glutathione modifiers, buthionine sulfoxamine (BSO) and N-acetylcysteine (NAC), are involved in regulation of cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) in proliferating mesenchymal stem cells (MSCs). Cellular glutathione was manipulated during a 14-day culture using BSO, NAC and silymarin. At intervals of 2, 7 and 14 days, cells were collected and COX-2 and iNOS levels were measured. In parallel, generation of cellular H₂O₂ and glutathione were measured. Supplementation of the culture media with BSO caused a dose-dependent decrease in MSC proliferation, whereas NAC or silymarin elevated the proliferation (p < 0.05). Treatment of MSC with NAC or silymarin caused a significant decrease in COX-2 levels. However, COX-2 levels in cells treated with high levels of NAC (1.0 mM) were significantly lower than those in MSCs treated with high levels of silymarin (100 μM). BSO (1.0 and 5.0 μM) caused a significant increase in COX-2 on days 2, 7 and 14. BSO caused a significant increase in iNOS, whereas NAC or silymarin decreased cellular iNOS. Overall result show that glutathione, iNOS and COX-2 in proliferating MSCs are affected by silymarin treatment. It appears that glutathione is the main target of silymarin, and in consequence iNOS and COX-2 are affected in response to silymarin treatment.

Matsuda T, Ferreri K, Todorov I, Kuroda Y, Smith CV, Kandeel F, Mullen Y (2005) Silymarin protects pancreatic β-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endocrinology 146(1):175–185PubMedCrossRef

Kiruthiga PV, Shafreen RB, Pandian SK, Devi KP (2007) Silymarin protection against major reactive oxygen species released by environmental toxins: exogenous H₂O₂ exposure in erythrocytes. Basic Clin Pharmacol Toxicol 100:414–419PubMedCrossRef

Fraschini F, Demartini G, Esposti D (2002) Pharmacology of silymarin. Clin Drug Invest 22(1):51–65CrossRef

Jones DP (2002) Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 348:93–112PubMedCrossRef

Walter HW, Yan C, Dean PJ (2003) Redox state of glutathione and thioredoxin in differentiation and apoptosis. BioFactors 17:307–314CrossRef

Yuan Y, Tzeng E, Billiar TR (2006) Distinct roles of different nitric oxide synthase isoforms in regulating hematopoietic stem cell function in vivo. Nitric Oxide 14:7CrossRef

Lee HW, Kim SY, Kim AY, Lee EJ, Choi JY, Kim JB (2009) Tissue-specific stem cells adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells 27(9):2254–2262PubMedCrossRef

Libby P, Warner SJ, Friedman GB (1988) Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth inhibitory prostanoids. J Clin Invest 81:487–498PubMedCrossRef

Schror K, Weber AA (1997) Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 48:63–91PubMed

10.

Yan Z, Hansson GK (1998) Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ Res 82:21–29PubMed

11.

Rizvi MA, Myers PR (1997) Nitric oxide modulates basal and endothein-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol 29:1779–1789PubMedCrossRef

12.

Gansauge S, Gansauge F, Nussler AK, Rau B, Poch B, Schoenberg MH, Beger HG (1997) Exogenous, but not endogenous, nitric oxide increases proliferation rates in senescent human fibroblasts. FEBS Lett 410:160–164PubMedCrossRef

13.

Sigala F, Papalambros E, Kotsinas A, Andreadou I, Sigalas P, Kremastinos D, Bastounis E, Gorgoulis VG (2005) Relationship between iNOS expression and aortic cell proliferation and apoptosis in an elastase-induced model of aorta aneurysm and the effect of 1400 W administration. Surgery 137(4):447–456PubMedCrossRef

14.

Kasper HU, Wolf H, Drebber U, Wolf HK, Kern MA (2004) Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density. World J Gastroenterol 10(13):1918–1922PubMed

15.

Abe T, Hikiji H, Shin WS, Koshikiya N, Shima S, Nakata J, Susami T, Takato T, Toyo-oka T (2003) Targeting of iNOS with antisense DNA plasmid reduces cytokine-induced inhibition of osteoblastic activity. Am J Physiol Endocrinol Metab 285(3):E614–E621PubMed

16.

Kolodziejski PJ, Koo JS, Eissa NT (2004) Regulation of inducible nitric oxide synthase by rapid cellular turnover and cotranslational down-regulation by dimerization inhibitors. Proc Natl Acad Sci USA 101(52):18141–18146PubMedCrossRef

17.

Kang JS, Jeon YJ, Kim HM, Han SH, Yang KH (2002) Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 302(1):138–144PubMedCrossRef

18.

Zhao J, Sharma Y, Agarwal R (1999) Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol Carcinog 26(4):321–333PubMedCrossRef

19.

Ramakrishnan G, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T (2008) Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol Cell Biochem 313(1–2):53–61PubMedCrossRef

20.

Wellington K, Jarvis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15(7):465–489PubMedCrossRef

21.

Pradhan SC, Girish C (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124(5):491–504PubMed

22.

Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26(6B):4457–4498PubMed

23.

Li LH, Wu LJ, Tashiro SI, Onodera S, Uchiumi F, Ikejima T (2007) Activation of the SIRT1 pathway and modulation of the cell cycle were involved in silymarin’s protection against UV-induced A375–S2 cell apoptosis. J Asian Nat Prod Res 9:245–252PubMedCrossRef

24.

Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R (2007) p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 6(10):2696–2707PubMedCrossRef

25.

Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R (2009) Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 8(8):2366–2374PubMedCrossRef

26.

Deep G, Oberlies NH, Kroll DJ, Agarwal RI (2008) Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer 123(1):41–50PubMedCrossRef

27.

Starvaggi Cucuzza L, Motta M, Miretti S, Macchi E, Martignani E, Accornero P, Baratta M (2010) Positive effect of silymarin on cell growth and differentiation in bovine and murine mammary cells. J Anim Physiol Anim Nutr (Berl) 94(1):111–117CrossRef

28.

Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25(7):1053–1069PubMedCrossRef

29.

Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T (2009) Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 42(2):229–240PubMedCrossRef

30.

Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY, Jerome KR, Polyak SJ (2010) Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 138(2):671–681PubMedCrossRef

31.

Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Sajjadi SE, Hourfar H, Moayedi B (2006) Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from β-thalassemia major patients. Int Immunopharmacol 6(8):1305–1310PubMedCrossRef

32.

He Q, Kim J, Sharma RP (2004) Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. Toxicol Sci 80(2):335–342PubMedCrossRef

33.

Tamayo C, Diamond S (2007) Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther 6(2):146–157PubMedCrossRef

34.

Tunca R, Sozmen M, Citil M, Karapehlivan M, Erginsoy S, Yapar K (2009) Pyridine induction of cytochrome P450 1A1, iNOS and metallothionein in Syrian hamsters and protective effects of silymarin. Exp Toxicol Pathol 61(3):243–255PubMedCrossRef

35.

Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R (2008) Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther 7(7):1817–1826PubMedCrossRef

36.

Wang HJ, Wei XF, Jiang YY, Huang H, Yang Y, Fan SM, Zang LH, Tashiro S, Onodera S, Ikejima T (2010) Silibinin induces the generation of nitric oxide in human breast cancer MCF-7 cells. Free Radic Res 44(5):577–584PubMedCrossRef

37.

Kazemnejad S, Allameh A, Soleimani M, Gharehbaghian A, Mohammadi Y, Amirizadeh N, Jazayery M (2009) Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold. J Gastroentrol Hepatol 24:278–287CrossRef

38.

Kim JW, Kim SY, Park SY, Kim YM, Kim JM, Lee MH, Ryu HM (2004) Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol 83(12):733–738PubMedCrossRef

39.

Covas DT, Siufi JLC, Silva ARL (2003) Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res 36:1179–1183PubMedCrossRef

40.

Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77PubMedCrossRef

41.

Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502–522PubMedCrossRef

42.

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRef

43.

Ahmadi-Ashtiani HR, Allameh A, Hamidipour N, Rastegar H, Soleimani M (2010) Increasing rate of human bone marrow mesenchymal stem cell proliferation in the presence of silymarin. J Med Plants 9(34):156–164

44.

Iemata M, Takarada T, Hinoi E, Taniura H, Yoneda Y (2007) Suppression by glutamate of proliferative activity through glutathione depletion mediated by the cysteine/glutamate antiporter in mesenchymal C3H10T1/2 stem cells. J Cell Physiol 213:721–729PubMedCrossRef

45.

Smith J, Ladi E, Mayer-Pröschel M, Noble M (2000) Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci USA 97(18):10032–10037PubMedCrossRef

46.

Valenzuela A, Aspillaga M, Vial S, Guerra R (1989) Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med 55(5):420–422PubMedCrossRef

47.

Ji AR, Ku SY, Cho MS, Kim YY, Kim YJ, Oh SK, Kim SH, Moon SY, Choi YM (2010) Reactive oxygen species enhance differentiation of human embryonic stem cells into mesendodermal lineage. Exp Mol Med 42:175–186PubMedCrossRef

48.

Ho YC, Chang YC (2006) Regulation of nicotine-induced cyclooxygenase-2 protein expression in human gingival fibroblasts. Acta Pharmacol Sin 27(4):409–413PubMedCrossRef

49.

Jourdan KB, Evans TW, Lamb NJ, Goldstraw P, Mitchell JA (1999) Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells. Am J Respir Cell Mol Biol 21(1):105–110PubMed

50.

Yang X, Sheares KK, Davie N, Upton PD, Taylor GW, Horsley J, Wharton J, Morrell NW (2002) Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 27(6):688–696PubMed

51.

Xu Z, Choudhary S, Voznesensky O, Mehrotra M, Woodard M, Hansen M, Herschman H, Pilbeam C (2006) Overexpression of Cox-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res 66(13):6657–6664PubMedCrossRef

52.

Wang R, Wang X, Lin F, Gao P, Dong K, Zhang HZ (2008) shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem 317:179–188PubMedCrossRef

53.

Collesellia D, Bijuklicb K, Mosheimerb BA, Kählera CM (2006) Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Exp Cell Res 312(15):2933–2941CrossRef

54.

Harbrecht BG, Di Silvio M, Chough V, Kim YM, Simmons RL, Billiar TR (1997) Glutathione regulates nitric oxide synthase in cultured hepatocytes. Ann Surg 225(1):76–87PubMedCrossRef

55.

Chen G, Wang S, Warner T (2000) Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. Free Radic Res 32(3):223–234PubMedCrossRef

Titel: Inhibition of cyclooxygenase-2 and inducible nitric oxide synthase by silymarin in proliferating mesenchymal stem cells: comparison with glutathione modifiers
verfasst von: Hamidreza Ahmadi-Ashtiani
Abdolamir Allameh
Hosein Rastegar
Masoud Soleimani
Elham Barkhordari
Publikationsdatum: 01.01.2012
Verlag: Springer Japan
Erschienen in: Journal of Natural Medicines / Ausgabe 1/2012
Print ISSN: 1340-3443
Elektronische ISSN: 1861-0293
DOI: https://doi.org/10.1007/s11418-011-0554-6

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells

Aqueous-methanolic extract of sweet flag (Acorus calamus) possesses cardiac depressant and endothelial-derived hyperpolarizing factor-mediated coronary vasodilator effects

Genetic diversity of Centella asiatica in China analyzed by inter-simple sequence repeat (ISSR) markers: combination analysis with chemical diversity

Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo

Insights into mechanisms underlying the gut and airways modulatory effects of Swertia chirata

New advanced glycation end-products inhibitors from Dichrostachys cinerea Wight & Arn.